Literature DB >> 19233141

Functional differences between two classes of oncogenic mutation in the PIK3CA gene.

Claire Chaussade1, Kitty Cho, Claire Mawson, Gordon W Rewcastle, Peter R Shepherd.   

Abstract

PIK3CA codes for the p110alpha isoform of class-IA PI 3-kinase and oncogenic mutations in the helical domain and kinase domain are common in several cancers. We studied the biochemical properties of a common helical domain mutant (E545K) and a common kinase domain mutant (H1047R). Both retain the ability to autophosphorylate Ser608 of p85alpha and are also inhibited by a range of PI 3-kinase inhibitors (Wortmannin, LY294002, PI-103 and PIK-75) to a similar extent as WT p110alpha. Both mutants display an increased V(max) but while a PDGF derived diphosphotyrosylpeptide caused an increase in V(max) for WT p85alpha/p110alpha it did not for the E545K variant and actually decreased V(max) for the H1047R variant. Further, the E545K mutant was activated by H-Ras whereas the H1047R mutant was not. Together these results suggest helical domain mutants are in a state mimicking activation by growth factors whereas kinase domain mutants mimic the state activated by H-Ras.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19233141     DOI: 10.1016/j.bbrc.2009.02.081

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  30 in total

1.  Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase.

Authors:  Minghao Sun; Jonathan R Hart; Petra Hillmann; Marco Gymnopoulos; Peter K Vogt
Journal:  Cell Cycle       Date:  2011-11-01       Impact factor: 4.534

Review 2.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

3.  PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis.

Authors:  Arantza Fariña Sarasqueta; Eliane C M Zeestraten; Tom van Wezel; Gesina van Lijnschoten; Ronald van Eijk; Jan Willem T Dekker; Peter J K Kuppen; Ines J Goossens-Beumer; Valery E P P Lemmens; Cornelis J H van de Velde; Harm J T Rutten; Hans Morreau; A J C van den Brule
Journal:  Cell Oncol (Dordr)       Date:  2011-08-10       Impact factor: 6.730

4.  Definition of the binding mode of phosphoinositide 3-kinase α-selective inhibitor A-66S through molecular dynamics simulation.

Authors:  Xiaoli Bian; Wangqing Dong; Yang Zhao; Rui Sun; Wanjun Kong; Yiping Li
Journal:  J Mol Model       Date:  2014-03-16       Impact factor: 1.810

Review 5.  The regulation of class IA PI 3-kinases by inter-subunit interactions.

Authors:  Jonathan M Backer
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 6.  Phosphatidylinositol 3-kinase: the oncoprotein.

Authors:  Peter K Vogt; Jonathan R Hart; Marco Gymnopoulos; Hao Jiang; Sohye Kang; Andreas G Bader; Li Zhao; Adam Denley
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

7.  Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.

Authors:  Ignacia Echeverria; Yunlong Liu; Sandra B Gabelli; L Mario Amzel
Journal:  FEBS J       Date:  2015-07-24       Impact factor: 5.542

8.  Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.

Authors:  Li Zhao; Peter K Vogt
Journal:  Cell Cycle       Date:  2010-02-01       Impact factor: 4.534

9.  Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.

Authors:  Huan Pang; Rory Flinn; Antonia Patsialou; Jeffrey Wyckoff; Evanthia T Roussos; Haiyan Wu; Maria Pozzuto; Sumanta Goswami; John S Condeelis; Anne R Bresnick; Jeffrey E Segall; Jonathan M Backer
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

10.  FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

Authors:  Lucie C Kompier; Irene Lurkin; Madelon N M van der Aa; Bas W G van Rhijn; Theo H van der Kwast; Ellen C Zwarthoff
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.